Formoterol fumarate dihydrate; Budesonide - search results

bufomix easyhaler, 160 micrograms/4.5 micrograms/inhalation, inhalation powder

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 4.5 µg budesonide 160 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

symbicort 200 micrograms/6 micrograms per inhalation, pressurised inhalation suspension

astrazeneca ab se-151 85, södertälje, sweden - budesonide, formoterol fumarate, dihydrate - pressurised inhalation, suspension - budesonide 200 µg/spray formoterol fumarate dihydrate 6 µg/spray - drugs for obstructive airway diseases

Malta - English - Medicines Authority

bufomix easyhaler, 320 micrograms/9 micrograms/inhalation, inhalation powder

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 9 µg budesonide 320 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

bufar easyhaler inhalation powder 160/4.5mcg/inhalatio

Malta - English - Medicines Authority

bufar easyhaler inhalation powder 320/9 mcg/inhalation

Malta - English - Medicines Authority

bufomix easyhaler inhalation powder 80/4.5mcg

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - inhalation powder - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

bufar easyhaler inhalation powder 80/4.5mcg

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - prolonged-release tablet - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

Canada - English - Health Canada

glycopyrronium / formoterol fumarate dihydrate pressurized inhalation suspension aerosol, metered dose

astrazeneca canada inc - formoterol fumarate dihydrate; glycopyrronium (glycopyrronium bromide) - aerosol, metered dose - 5.8mcg; 8.3mcg - formoterol fumarate dihydrate 5.8mcg; glycopyrronium (glycopyrronium bromide) 8.3mcg - antimuscarinics antispasmodics

Australia - English - Department of Health (Therapeutic Goods Administration)

fostair 100/6 beclometasone dipropionate 100 microgram and formoterol fumarate dihydrate 6 microgram pressurised inhalation solution

chiesi australia pty ltd - beclometasone dipropionate, quantity: 100 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches). copd (fostair 100/6 only) symptomatic treatment of adults with severe copd (fev1 less than 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Australia - English - Department of Health (Therapeutic Goods Administration)

fostair 200/6 beclometasone dipropionate 200 microgram and formoterol fumarate dihydrate 6 microgram pressurised inhalation solution

chiesi australia pty ltd - beclometasone dipropionate, quantity: 200 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches).